Replies to post #215180 on Biotech Values

[ghmm]

NKTR:

Yes they said they started enrolling (the sarcoma study) a few weeks ago.

They'll actually have (at least) 4 separate trials with 214 combo reporting data in '18
. PIVOT-02 (combo with Nivo)
. The Sarcoma study (combo with Nivo)
. PROPEL (combo Tecentriq or Keytruda)
. REVEAL (combo with NKTR-262)

The takeda program has some programs with approved agents so something may enter clinic in '18

THere was also a preclinical poster with a cancer vaccine (jbog posted an article)

Also they are looking at combo with other agents